On this page
What it is
A synthetic decapeptide identical to endogenous gonadotropin-releasing hormone, with a very short half-life measured in minutes.
How it is proposed to work
Binds GnRH receptors on pituitary gonadotrophs, stimulating LH and FSH release. Crucially the response depends on pulsatility: pulsatile delivery stimulates the axis, whereas continuous exposure downregulates receptors and suppresses it. Same molecule, opposite outcome, determined entirely by pattern.
Approved medical uses
Diagnostic assessment of pituitary gonadotropic function where approved. Availability has narrowed over time and varies by jurisdiction.
Human research
Each entry states what the study found and, separately, what it cannot show.
- Human open-label1994n = 292
Pulsatile GnRH for ovulation induction across anovulatory diagnoses
Finding. Pulsatile GnRH was given over 600 consecutive cycles to 292 anovulatory women, pooled across five diagnostic groups: primary hypogonadotropic amenorrhoea, other hypogonadotropic hypogonadisms, multifollicular ovary, polycystic ovary and other hyperandrogenic anovulations. Across the whole series the ovulatory rate was 75% and pregnancy occurred in 105 cycles, 18% per treatment cycle and 23% per ovulatory cycle. Outcomes tracked the diagnosis: ovulatory and pregnancy rates were higher in primary hypogonadotropic amenorrhoea, other hypogonadotropic hypogonadisms and multifollicular ovary, and lower in polycystic ovary and other hyperandrogenic anovulations. The report gives only that direction and no per-group rates, so none of these figures can be read as the rate for any single diagnosis. On safety the authors report that pulsatile GnRH did not cause ovarian hyperstimulation and that low-dose pulsatile GnRH carried a low incidence of multiple pregnancy (4 of the 105 pregnancies, 3.8%, none after GnRH-agonist suppression), but the abortion rate was 30% overall and highest in polycystic ovary at 45%.
Limitation. An uncontrolled consecutive treatment series run between 1984 and 1993, pooling five diagnostic groups whose results differed markedly, so the overall rates do not transfer to any single diagnosis; the single largest group was polycystic ovary at 85 patients and 172 cycles, and only 130 of the 292 patients had a hypogonadotropic diagnosis. GnRH was delivered by an indwelling intravenous pump in timed pulses, not by occasional injection, and this regimen is not reproducible with intermittent self-injection. In 228 of the 600 cycles pulsatile GnRH was preceded by GnRH-agonist suppression, which improved ovulatory rates only in polycystic ovary. Higher weight and insulin were associated with lower ovulatory and pregnancy rates, and higher LH and testosterone with lower ovulatory rates. The report measures ovulation and pregnancy, not restoration of gonadotropin secretion as such.
Preclinical research
Animal and laboratory work. Useful for generating hypotheses; it cannot establish that something works in people.
No preclinical studies catalogued.
Potential safety concerns
- CautionEstablished
The pulsatility requirement is the central practical issue. A dosing pattern that becomes effectively continuous suppresses the axis rather than supporting it — the opposite of the intended effect.
- CautionEstablished
It is a prescription medicine. Grey-sourced material carries the identity and concentration risks documented across this category.
Known interactions and contraindication considerations
- Interacts with any therapy affecting the HPG axis, including testosterone therapy and GnRH agonists or antagonists.
This list is not exhaustive and is not a substitute for a clinician reviewing your full medication history.
Regulatory status
Status is shown per jurisdiction and is accurate only as of the date stated. Where a compound is approved, the approval is bound to a specific formulation, manufacturer and indication — shown in the detail column.
| Jurisdiction | Standing | Detail |
|---|---|---|
United States FDA | Approved — other indication as of 1 Jun 2026 | Has held approvals for diagnostic assessment of pituitary gonadotropic function. Several presentations have been discontinued, so current availability and approved indication must be verified rather than assumed. |
European Union EMA | Approved — other indication as of 1 Jun 2026 | Approval status differs between member states. Verify nationally. |
India CDSCO | Restricted as of 1 Jun 2026 | Prescription-only where available. Verify current CDSCO status. |
How it is being used
What the grey community actually runs, the reasoning they give, and our read on whether it follows from known biology. This is observation, not evidence, and not a recommendation.
HPG-axis support as an alternative to hCG
What is run
Frequent small administrations, sometimes several times daily, attempting to mimic natural pulsatile release.
Their mechanistic reasoning
That acting at the top of the axis is more physiological than hCG's action at the bottom, since it engages the pituitary rather than bypassing it.
Reported in the community’s own terms. Not our position.
Stacked with
- Testosterone therapy—Same countermeasure context as hCG.
Regimen shape
- Dose
- figure withheld
- Scale
- Microgram-scale
- Route
- Subcutaneous injection
- Frequency
- Multiple times daily in some protocols
- Timing
- Spread to approximate pulsatility
- Duration
- Continuous alongside the underlying therapy
Our read
The 'more physiological' argument is appealing and the underlying physiology is right, but it collides with a hard pharmacological fact: the response depends entirely on pulsatility, and gonadorelin's half-life is measured in minutes. Clinical use that works relies on pump-delivered pulses. Intermittent self-injection is unlikely to reproduce that, and a pattern that drifts toward continuous exposure downregulates the axis — achieving the opposite of the intent. hCG's longer action is a practical advantage here, not a compromise.
What the community reports
The comparison is between how sure the community is and how much is actually known — evidence strength, not direction. A compound can have solid research that came out negative.
Promoted heavily by some telehealth clinics as more physiological, and doubted by people who understand the pulsatility requirement. The disagreement is substantive rather than tribal.
Commonly reported as helping
- Maintained testicular volume, reported by some users
- Preferred by people who found hCG raised oestradiol too much
Also reported, when it goes wrong
- Many report no maintained testicular volume at all
- Injection frequency described as impractical
- Widespread suspicion that it underperforms hCG
Why these reports can mislead
The split in reports is what the pharmacology predicts: a very short half-life means outcome depends heavily on dosing pattern, so people following different schedules genuinely are running different interventions. The disagreement is real rather than a reporting artefact.
Direct quotations are not published here yet. We will only carry verbatim reports once they are sourced, dated and checked — an unattributed quote is a testimonial, and testimonials are exactly what this section exists to replace.
Watch for, in this use specifically
- A dosing pattern that becomes effectively continuous suppresses the axis instead of supporting it.
- Prescription medicine; grey supply carries the usual identity and concentration risks.
Active clinical trials
No registered trials currently tracked for Gonadorelin.
What remains unknown
The questions that would change our assessment if they were answered.
- How well do self-administered intermittent regimens approximate physiological pulsatility? Probably poorly, but this is not well studied.
- How does it compare with hCG for maintaining testicular function during testosterone therapy? Direct comparisons are limited.
References
Editorial change history
When we change a grade or a regulatory note, we log it here rather than editing quietly.
Dossier created.
Spotted something wrong? Tell us — we publish corrections.